Franklin Templeton Group of Funds > FRANKLIN STRATEGIC SERIES
Franklin Biotechnology Discovery Fund
$828.30M
Avg Monthly Net Assets
$975.79M
Total Assets
$34.73M
Total Liabilities
$941.06M
Net Assets
Franklin Biotechnology Discovery Fund is a Mutual Fund in FRANKLIN STRATEGIC SERIES
from Franklin Templeton Group of Funds,
based in California,
United States of America.
The fund has four share classes
and monthly net assets of $828.30M.
On September 23rd, 2024 it reported 95 holdings, the largest
being Amgen, Inc. (8.2%), Regeneron Pharmaceuticals, Inc. (7.1%) and Vertex Pharmaceuticals, Inc. (6.0%).
Data provided by Fincoded.
Share Classes
| Name | Class/Contract ID | Ticker | Monthly Returns (2 years) |
|---|---|---|---|
| Advisor Class | C000081539 | FTDZX | |
| Class A | C000018631 | FBDIX | |
| Class C | C000141458 | FBTDX | |
| Class R6 | C000128862 | FRBRX |
Holdings
From latest NPORT-P, filed September 23rd, 2024 for period ending July 31st, 2024.
Historic holdings data available from Fincoded.
| Name | Profile | Category | Country | Value $USD | # Shares | % of Fund |
|---|---|---|---|---|---|---|
| 89bio, Inc. | Long | Equity-common | US | $2M | 254K | 0.25 |
| Abivax SA | Long | Equity-common | FR | $6M | 480K | 0.60 |
| Achieve Life Sciences, Inc. | Long | Equity-common | US | $11M | 2M | 1.15 |
| Achieve Life Sciences, Inc. | Long | Warrant | US | $2M | 2M | 0.18 |
| Acumen Pharmaceuticals, Inc. | Long | Equity-common | US | $3M | 826K | 0.29 |
| Adverum Biotechnologies, Inc. | Long | Equity-common | US | $5M | 625K | 0.49 |
| Alector, Inc. | Long | Equity-common | US | $2M | 303K | 0.19 |
| Alnylam Pharmaceuticals, Inc. | Long | Equity-common | US | $10M | 42K | 1.05 |
| Alto Neuroscience, Inc. | Long | Equity-common | US | $2M | 210K | 0.24 |
| Alto Neuroscience, Inc. | Long | Equity-common | US | $2M | 165K | 0.19 |
| Amgen, Inc. | Long | Equity-common | US | $77M | 232K | 8.19 |
| AnaptysBio, Inc. | Long | Equity-common | US | $6M | 161K | 0.59 |
| Apellis Pharmaceuticals, Inc. | Long | Equity-common | US | $3M | 77K | 0.33 |
| Apogee Therapeutics, Inc. | Long | Equity-common | US | $10M | 207K | 1.07 |
| Applied Therapeutics, Inc. | Long | Equity-common | US | $20M | 3M | 2.18 |
| Aquestive Therapeutics, Inc. | Long | Equity-common | US | $4M | 994K | 0.41 |
| Arcutis Biotherapeutics, Inc. | Long | Equity-common | US | $15M | 2M | 1.63 |
| Argenx SE | Long | Equity-common | NL | $23M | 44K | 2.44 |
| ARS Pharmaceuticals, Inc. | Long | Equity-common | US | $11M | 1M | 1.18 |
| Artiva Biotherapeutics, Inc. | Long | Equity-common | US | $2M | 150K | 0.19 |
| Artiva Biotherapeutics, Inc. | Long | Equity-common | US | $510K | 43K | 0.05 |
| Ascendis Pharma A/S | Long | Equity-common | DK | $34M | 255K | 3.61 |
| AstraZeneca plc | Long | Equity-common | GB | $27M | 336K | 2.83 |
| Aura Biosciences, Inc. | Long | Equity-common | US | $6M | 568K | 0.62 |
| Avantor, Inc. | Long | Equity-common | US | $10M | 384K | 1.09 |
| Benitec Biopharma, Inc. | Long | Equity-common | US | $5M | 573K | 0.54 |
| Benitec Biopharma, Inc. | Long | Equity-common | US | $3M | 311K | 0.29 |
| Benitec Biopharma, Inc. | Long | Equity-common | US | $1M | 311K | 0.16 |
| Benitec Biopharma, Inc., Series II | Long | Warrant | AU | $3M | 7M | 0.29 |
| Biogen, Inc. | Long | Equity-common | US | $28M | 129K | 2.93 |
| Carmot Therapeutics, Inc. | Long | Equity-common | US | $406K | 83K | 0.04 |
| Centessa Pharmaceuticals plc | Long | Equity-common | GB | $2M | 202K | 0.23 |
| Centessa Pharmaceuticals plc | Long | Equity-common | GB | $2M | 190K | 0.21 |
| CG oncology, Inc. | Long | Equity-common | US | $7M | 195K | 0.69 |
| Cogent Biosciences, Inc., Series B | Long | Equity-common | US | $3M | 340K | 0.34 |
| Contineum Therapeutics, Inc. | Long | Equity-common | US | $6M | 295K | 0.63 |
| Contineum Therapeutics, Inc., Class A | Long | Equity-common | US | $4M | 217K | 0.46 |
| Crinetics Pharmaceuticals, Inc. | Long | Equity-common | US | $12M | 229K | 1.29 |
| Cullinan Therapeutics, Inc. | Long | Equity-common | US | $11M | 552K | 1.14 |
| Day One Biopharmaceuticals, Inc. | Long | Equity-common | US | $12M | 866K | 1.32 |
| Day One Biopharmaceuticals, Inc. | Long | Equity-common | US | $3M | 227K | 0.33 |
| Dyne Therapeutics, Inc. | Long | Equity-common | US | $15M | 355K | 1.62 |
| Engene Holdings, Inc. | Long | Equity-common | CA | $3M | 272K | 0.27 |
| EyePoint Pharmaceuticals, Inc. | Long | Equity-common | US | $10M | 976K | 1.02 |
| Gilead Sciences, Inc. | Long | Equity-common | US | $31M | 404K | 3.27 |
| Guardant Health, Inc. | Long | Equity-common | US | $11M | 323K | 1.21 |
| Heron Therapeutics, Inc. | Long | Equity-common | US | $4M | 1M | 0.38 |
| HilleVax, Inc. | Long | Equity-common | US | $1M | 691K | 0.13 |
| Illumina, Inc. | Long | Equity-common | US | $10M | 80K | 1.04 |
| Immunovant, Inc. | Long | Equity-common | US | $10M | 358K | 1.10 |
| Insmed, Inc. | Long | Equity-common | US | $35M | 486K | 3.76 |
| Institutional Fiduciary Trust - Money Market Portfolio | Long | Short-term investment vehicle | US | $6M | 6M | 0.59 |
| Institutional Fiduciary Trust Money Market Portfolio | Long | Short-term investment vehicle | US | $28M | 28M | 2.97 |
| Intra-Cellular Therapies, Inc. | Long | Equity-common | US | $28M | 355K | 2.97 |
| Jade Biosciences GmbH | Long | Debt | DE | $5M | – | 0.53 |
| Jasper Therapeutics, Inc. | Long | Equity-common | US | $4M | 237K | 0.47 |
| Jazz Pharmaceuticals plc | Long | Equity-common | IE | $24M | 216K | 2.53 |
| Keros Therapeutics, Inc. | Long | Equity-common | US | $7M | 136K | 0.72 |
| Kura Oncology, Inc. | Long | Equity-common | US | $6M | 282K | 0.62 |
| Kyverna Therapeutics, Inc. | Long | Equity-common | US | $2M | 245K | 0.23 |
| Lycia LLC, Series C | Long | Equity-common | JP | $2M | 859K | 0.19 |
| Marinus Pharmaceuticals, Inc. | Long | Equity-common | US | $2M | 1M | 0.18 |
| Merus NV | Long | Equity-common | NL | $27M | 500K | 2.82 |
| Mineralys Therapeutics, Inc. | Long | Equity-common | US | $7M | 555K | 0.73 |
| Mirum Pharmaceuticals, Inc. | Long | Equity-common | US | $13M | 313K | 1.35 |
| Neurocrine Biosciences, Inc. | Long | Equity-common | US | $24M | 167K | 2.51 |
| Nuvalent, Inc., Class A | Long | Equity-common | US | $5M | 60K | 0.51 |
| Nuvation Bio, Inc. | Long | Warrant | US | $32K | 115K | 0.00 |
| Ocular Therapeutix, Inc. | Long | Equity-common | US | $3M | 410K | 0.37 |
| ORIC Pharmaceuticals, Inc. | Long | Equity-common | US | $3M | 275K | 0.33 |
| Oruka Therapeutics, Inc. | Long | Equity-common | US | $4M | 409K | 0.47 |
| Pliant Therapeutics, Inc. | Long | Equity-common | US | $2M | 159K | 0.24 |
| Praxis Precision Medicines, Inc. | Long | Equity-common | US | $8M | 139K | 0.85 |
| PTC Therapeutics, Inc. | Long | Equity-common | US | $16M | 481K | 1.73 |
| Regeneron Pharmaceuticals, Inc. | Long | Equity-common | US | $67M | 62K | 7.14 |
| Relmada Therapeutics, Inc. | Long | Equity-common | US | $1M | 374K | 0.15 |
| Revance Therapeutics, Inc. | Long | Equity-common | US | $7M | 2M | 0.69 |
| Rocket Pharmaceuticals, Inc. | Long | Equity-common | US | $8M | 345K | 0.89 |
| Sanofi SA, Escrow Account | Long | Equity-common | CO | $0 | 2M | – |
| Sarepta Therapeutics, Inc. | Long | Equity-common | US | $12M | 84K | 1.26 |
| Sartorius AG | Long | Equity-preferred | DE | $3M | 9K | 0.28 |
| Sartorius Stedim Biotech | Long | Equity-common | FR | $2M | 10K | 0.21 |
| Shattuck Labs, Inc. | Long | Equity-common | US | $2M | 506K | 0.21 |
| Spyre Therapeutics, Inc. | Long | Equity-common | US | $6M | 220K | 0.64 |
| Spyre Therapeutics, Inc. | Long | Equity-common | US | $1M | 54K | 0.16 |
| Structure Therapeutics, Inc. | Long | Equity-common | KY | $5M | 141K | 0.56 |
| Structure Therapeutics, Inc. | Long | Equity-common | KY | $1M | 35K | 0.14 |
| Syndax Pharmaceuticals, Inc. | Long | Equity-common | US | $7M | 321K | 0.77 |
| Thermo Fisher Scientific, Inc. | Long | Equity-common | US | $5M | 9K | 0.56 |
| Ultragenyx Pharmaceutical, Inc. | Long | Equity-common | US | $3M | 63K | 0.30 |
| uniQure NV | Long | Equity-common | NL | $4M | 528K | 0.43 |
| Vaxcyte, Inc. | Long | Equity-common | US | $17M | 210K | 1.76 |
| Vertex Pharmaceuticals, Inc. | Long | Equity-common | US | $57M | 115K | 6.04 |
| Xenon Pharmaceuticals, Inc. | Long | Equity-common | CA | $4M | 93K | 0.43 |
| Zealand Pharma A/S, Class A | Long | Equity-common | DK | $9M | 70K | 1.00 |
Address
FRANKLIN STRATEGIC SERIES
ONE FRANKLIN PARKWAY
SAN MATEO
California
94403-1906
United States of America
Websites
Directors
Terrence J. Checki
Rupert H. Johnson, Jr.
J. Michael Luttig
Edith E. Holiday
Harris J. Ashton
Gregory E. Johnson
Mary C. Choksi
Larry D. Thompson
Valerie M. Williams
Transfer Agents
FIS Investor Services, LLC /TA
Franklin Templeton Investor Services, LLC
Pricing Services
LSEG
Custodians
The Bank of New York Mellon
Franklin Templeton Investor Services LLC
JPMorgan Chase Bank, N.A.
Shareholder Servicing Agents
Franklin Templeton Investor Services, LLC
Admins
FRANKLIN TEMPLETON SERVICES, LLC
JPMorgan Chase Bank, N.A.
Brokers
Rosenblatt Securities Inc.
Merrill Lynch, Pierce, Fenner & Smith Inc.
Citigroup Global Markets Inc.
Sanford C. Bernstein & Co., LLC
Allen & Company LLC
William Blair & Company, L.L.C.
State Street Global Markets, LLC
Morgan Stanley & Co. LLC
UBS Securities LLC
Jefferies LLC